JP2020530497A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530497A5
JP2020530497A5 JP2020530441A JP2020530441A JP2020530497A5 JP 2020530497 A5 JP2020530497 A5 JP 2020530497A5 JP 2020530441 A JP2020530441 A JP 2020530441A JP 2020530441 A JP2020530441 A JP 2020530441A JP 2020530497 A5 JP2020530497 A5 JP 2020530497A5
Authority
JP
Japan
Prior art keywords
patent document
vol
page
international
documents cited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020530441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530497A (ja
JP7424639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046203 external-priority patent/WO2019032958A1/en
Publication of JP2020530497A publication Critical patent/JP2020530497A/ja
Publication of JP2020530497A5 publication Critical patent/JP2020530497A5/ja
Priority to JP2023123302A priority Critical patent/JP7778750B2/ja
Application granted granted Critical
Publication of JP7424639B2 publication Critical patent/JP7424639B2/ja
Priority to JP2025168516A priority patent/JP2026012715A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020530441A 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態 Active JP7424639B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023123302A JP7778750B2 (ja) 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2025168516A JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023123302A Division JP7778750B2 (ja) 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Publications (3)

Publication Number Publication Date
JP2020530497A JP2020530497A (ja) 2020-10-22
JP2020530497A5 true JP2020530497A5 (cg-RX-API-DMAC7.html) 2021-09-09
JP7424639B2 JP7424639B2 (ja) 2024-01-30

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020530441A Active JP7424639B2 (ja) 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2023123302A Active JP7778750B2 (ja) 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2025168516A Pending JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023123302A Active JP7778750B2 (ja) 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2025168516A Pending JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Country Status (16)

Country Link
US (3) US11136334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3665176B1 (cg-RX-API-DMAC7.html)
JP (3) JP7424639B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250070131A (cg-RX-API-DMAC7.html)
CN (2) CN117362305A (cg-RX-API-DMAC7.html)
AU (3) AU2018313259B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072240A1 (cg-RX-API-DMAC7.html)
DK (1) DK3665176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974328T3 (cg-RX-API-DMAC7.html)
FI (1) FI3665176T3 (cg-RX-API-DMAC7.html)
IL (2) IL272556B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020001547A (cg-RX-API-DMAC7.html)
PL (1) PL3665176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3665176T (cg-RX-API-DMAC7.html)
WO (1) WO2019032958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2013515737A (ja) 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法

Similar Documents

Publication Publication Date Title
CN114072411A (zh) 作为Wee1抑制剂的嘧啶衍生物
JP2019502892A5 (cg-RX-API-DMAC7.html)
PH12017500635A1 (en) Aminopyridyloxypyrazole compounds
MX2010007604A (es) Pirimidinas como inhibidores de cinasa.
MY148521A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
NO20083690L (no) Hydantoin baserte kinase-inhibitorer
WO2009087212A3 (en) Pyridine derivatives
JP2013540293A5 (cg-RX-API-DMAC7.html)
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
CA2672094C (en) Methods and apparatus for identifying subject matter in view data
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JP2013519136A5 (cg-RX-API-DMAC7.html)
WO2012068529A3 (en) Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
EA201070691A1 (ru) Амидные соединения в качестве активаторов противовирусных препаратов
NZ624636A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2006015860A3 (en) Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor
MX2017010348A (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
NO20090073L (no) 1,3-disubstitue 4-metyl-1H-pyrol-2-karboksamider og deres anvendelse for fremstlling av medikamenter
PH12017501829A1 (en) Pharmaceutical formulations
MX394556B (es) Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
WO2020159889A9 (en) Srebp inhibitors comprising a thiophene central ring